Literature DB >> 28509299

Development of minimal-change glomerular disease and Hashimoto's thyroiditis during the treatment of sarcoidosis.

Fumiaki Ando1, Tomokazu Okado2, Eisei Sohara1, Tatemitsu Rai1, Shinichi Uchida1, Sei Sasaki1.   

Abstract

Minimal-change glomerular disease, sarcoidosis and autoimmune thyroid disease rarely occur in the same patient. We herein report a patient in which minimal-change glomerular disease and Hashimoto's thyroiditis developed during the treatment of sarcoidosis with steroids. A 66-year-old female was admitted to our hospital with symptoms of nephrotic syndrome. Nine months before admission, she was diagnosed as having ocular and pulmonary sarcoidosis, for which prednisolone at an initial dose of 40 mg/day was started. When the dose of prednisolone was tapered to 20 mg/day, she noticed swelling of the lower extremities. Examination confirmed the simultaneous occurrence of minimal-change glomerular disease and Hashimoto's thyroiditis, which were diagnosed based on kidney histology, ultrasonography of the thyroid gland and positive antithyroglobulin antibodies. We used intravenous methylprednisolone pulse therapy followed by 40 mg/day oral prednisolone. The patient achieved complete remission of nephrotic syndrome and steroids were tapered without relapse.

Entities:  

Keywords:  Hashimoto’s thyroiditis; Minimal-change glomerular disease; Sarcoidosis

Year:  2013        PMID: 28509299      PMCID: PMC5411556          DOI: 10.1007/s13730-013-0072-3

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  23 in total

1.  Simultaneous relapse of Graves' disease and minimal change glomerular disease.

Authors:  Steve Holt; Edward Kingdon; Daniel Morganstein; Paul Sweny
Journal:  Nephrol Dial Transplant       Date:  2002-04       Impact factor: 5.992

2.  Simultaneous occurrence of minimal change glomerular disease, sarcoidosis and Hashimoto's thyroiditis.

Authors:  A Nishimoto; Y Tomiyoshi; T Sakemi; F Kanegae; M Nakamura; Y Ikeda; K Shimazu; N Yonemitsu
Journal:  Am J Nephrol       Date:  2000 Sep-Oct       Impact factor: 3.754

Review 3.  Secondary minimal change disease.

Authors:  Richard J Glassock
Journal:  Nephrol Dial Transplant       Date:  2003-08       Impact factor: 5.992

Review 4.  Glucocorticoids and the Th1/Th2 balance.

Authors:  Ilia J Elenkov
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

5.  Prevalence of hypothyroidism and Graves disease in sarcoidosis.

Authors:  Alessandro Antonelli; Piera Fazzi; Poupak Fallahi; Silvia Martina Ferrari; Ele Ferrannini
Journal:  Chest       Date:  2006-08       Impact factor: 9.410

6.  Graves' disease and sarcoidosis in a patient with minimal-change glomerulonephritis.

Authors:  E Mündlein; T Greten; E Ritz
Journal:  Nephrol Dial Transplant       Date:  1996-05       Impact factor: 5.992

7.  Minimal-change disease in association with sarcoidosis.

Authors:  R G Parry; C Falk
Journal:  Nephrol Dial Transplant       Date:  1997-10       Impact factor: 5.992

8.  Sarcoidosis is a Th1/Th17 multisystem disorder.

Authors:  Monica Facco; Anna Cabrelle; Antonella Teramo; Valeria Olivieri; Marianna Gnoato; Sara Teolato; Elisa Ave; Cristina Gattazzo; Gian Paolo Fadini; Fiorella Calabrese; Gianpietro Semenzato; Carlo Agostini
Journal:  Thorax       Date:  2010-12-07       Impact factor: 9.139

Review 9.  Membranous glomerulonephritis associated with Graves' disease.

Authors:  B A Becker; A Z Fenves; N A Breslau
Journal:  Am J Kidney Dis       Date:  1999-02       Impact factor: 8.860

10.  High frequency of endocrine autoimmunity in patients with sarcoidosis.

Authors:  K I Papadopoulos; Y Hörnblad; H Liljebladh; B Hallengren
Journal:  Eur J Endocrinol       Date:  1996-03       Impact factor: 6.664

View more
  1 in total

1.  The diagnostic challenge of coexistent sarcoidosis and thyroid cancer - a retrospective study.

Authors:  Vera Wenter; Nathalie L Albert; Freba Ahmaddy; Marcus Unterrainer; Julia Hornung; Harun Ilhan; Peter Bartenstein; Christine Spitzweg; Nikolaus Kneidinger; Andrei Todica
Journal:  BMC Cancer       Date:  2021-02-07       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.